MA52889A - Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires - Google Patents

Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires

Info

Publication number
MA52889A
MA52889A MA052889A MA52889A MA52889A MA 52889 A MA52889 A MA 52889A MA 052889 A MA052889 A MA 052889A MA 52889 A MA52889 A MA 52889A MA 52889 A MA52889 A MA 52889A
Authority
MA
Morocco
Prior art keywords
modulation
post
cellular signaling
immune activity
increased immune
Prior art date
Application number
MA052889A
Other languages
English (en)
Inventor
Anthony Michael Barsotti
Alexandra Masu Cantley
Jason Park
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of MA52889A publication Critical patent/MA52889A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
MA052889A 2018-06-15 2019-06-14 Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires MA52889A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685770P 2018-06-15 2018-06-15
US201862781819P 2018-12-19 2018-12-19

Publications (1)

Publication Number Publication Date
MA52889A true MA52889A (fr) 2021-04-21

Family

ID=67138105

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052889A MA52889A (fr) 2018-06-15 2019-06-14 Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires

Country Status (9)

Country Link
US (1) US20210251994A1 (fr)
EP (1) EP3806848A2 (fr)
JP (1) JP2021528393A (fr)
KR (1) KR20210035805A (fr)
CN (1) CN112638375A (fr)
AU (1) AU2019287765A1 (fr)
CA (1) CA3103629A1 (fr)
MA (1) MA52889A (fr)
WO (1) WO2019241730A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915585A1 (fr) * 2020-05-26 2021-12-01 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Combinaisons thérapeutiques comprenant des agonistes de la ferroptose pour le traitement de troubles prolifératifs
CN113421613B (zh) * 2021-06-08 2024-06-18 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
CN117625547B (zh) * 2022-08-25 2024-06-28 广州百吉生物制药有限公司 联合表达gpx4的新一代嵌合抗原受体及其应用
CN115804772B (zh) * 2022-11-16 2024-04-26 山东大学 一种铁死亡抑制剂在抗病毒感染中的应用

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104E (fr)
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE19939653A1 (de) 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP2003510371A (ja) 1999-10-04 2003-03-18 カイロン コーポレイション 乾癬を処置するためのｃｄ４０アンタゴニスト
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US20020031512A1 (en) 2000-04-19 2002-03-14 M. C. Pasch CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP1717251B1 (fr) 2000-10-02 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Anticorps humains anti-CD40 pour le traitement des tumeurs malignes des lymphocytes B
DE10050935A1 (de) 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US20020102264A1 (en) 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
CA2423843A1 (fr) 2000-10-18 2002-04-25 Sloan-Kettering Institute For Cancer Research Utilisations d'anticorps monoclonal 8h9
WO2002047721A1 (fr) 2000-12-14 2002-06-20 Fujisawa Pharmaceutical Co., Ltd. Anticorps anti-cd28 silencieux et leur utilisation
PT1345969E (pt) 2000-12-26 2010-11-17 Inst Nat Sante Rech Med Anticorpos anti-cd28
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
CA2658221C (fr) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-cd40
WO2003029296A1 (fr) 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2466931A1 (fr) 2001-11-26 2003-06-05 Chiron Corporation Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
AU2003220079A1 (en) 2002-03-08 2003-09-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
DE10212108A1 (de) 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
CA2489004C (fr) 2002-06-13 2013-01-08 Crucell Holland B.V. Molecules de liaison agonistes capables de se lier au recepteur ox40 humain
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US6693136B1 (en) 2002-07-26 2004-02-17 Abbott Laboratories Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
EP1539237A4 (fr) 2002-07-30 2006-05-24 Bristol Myers Squibb Co Anticorps humanises contre le 4-1bb humain
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2004107618A2 (fr) 2003-05-23 2004-12-09 Wyeth Ligand du gitr et molecules et anticorps lies au ligand du gitr et leurs utilisations
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
EP1600164A3 (fr) 2003-09-22 2006-05-17 TeGenero AG Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20070110754A1 (en) 2003-11-04 2007-05-17 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
DE602004028272D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ATE476991T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
ATE516819T1 (de) 2003-11-04 2011-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von b-zell-bedingtem krebs
DE10352900A1 (de) 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
DK1707627T3 (da) 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
PT1836225E (pt) 2005-01-06 2012-01-10 Novo Nordisk As Agentes de ligação a kir e métodos de utilização dos mesmos
DK1835937T3 (da) 2005-01-06 2012-07-23 Novo Nordisk As Sammensætninger og fremgangsmåder til behandling af virusinfektion
EP2446897A1 (fr) 2005-01-06 2012-05-02 Novo Nordisk A/S Traitements de combinaison anti-KIR et procédés
US8518959B2 (en) 2005-01-25 2013-08-27 Prolexys Pharmaceuticals, Inc. Quinoxaline derivatives as antitumor agents
US20070161644A1 (en) 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
WO2006104677A2 (fr) 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Anticorps se liant a ov064 et leurs methodes d'utilisation
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
CA2602777C (fr) 2005-03-25 2018-12-11 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
US20060240006A1 (en) 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
CA2605745A1 (fr) 2005-04-27 2006-11-02 Robert J. Hickey Anticorps de l'isoforme de l'antigene nucleaire des cellules proliferatives cancereuses specifiques (pcnacs) et leurs utilisations
CN105315373B (zh) 2005-05-09 2018-11-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
US8333970B2 (en) 2005-05-18 2012-12-18 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
JP5208730B2 (ja) 2005-05-18 2013-06-12 ノバルティス アーゲー Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
KR100694508B1 (ko) 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
AU2006249305B2 (en) 2005-05-26 2012-10-18 Genentech, Inc. Humanized anti-CD40 antibodies and their methods of use
PL1907424T3 (pl) 2005-07-01 2015-12-31 Squibb & Sons Llc Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
CN101351478A (zh) 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
CN101325970B (zh) 2005-11-01 2013-08-14 诺华有限公司 抗cd40抗体的应用
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
BRPI0620601A2 (pt) 2005-12-08 2011-11-16 Medarex Inc anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e
CA2632698A1 (fr) 2005-12-09 2007-07-05 Seattle Genetics, Inc. Procedes d'utilisation d'agents de liaison de cd40
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
US20090170834A1 (en) 2005-12-22 2009-07-02 Prolexys Pharmaceuticals, Inc. Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
US20110008368A1 (en) 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
WO2007149476A2 (fr) 2006-06-19 2007-12-27 Trustees Of Columbia University In The City Of New York Déterminations de la mort cellulaire non apoptotique et leurs utilisations
KR100745488B1 (ko) 2006-07-04 2007-08-02 학교법인 울산공업학원 항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
WO2008013987A2 (fr) 2006-07-27 2008-01-31 Prolexys Pharmaceuticals, Inc. Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
AU2007334264A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
CN101578113B (zh) 2007-01-11 2015-04-22 诺和诺德公司 抗-kir抗体、制剂及其应用
CA2669412A1 (fr) 2007-01-23 2008-07-31 Xencor, Inc. Anticorps cd40 optimises et leurs procedes d'utilisation
WO2008103470A2 (fr) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Composés létaux dépendants du signal de ras oncogénique
WO2008116219A2 (fr) 2007-03-22 2008-09-25 Sloan-Kettering Institute For Cancer Research Utilisations de l'anticorps monoclonal 8h9
MX2009011996A (es) 2007-05-07 2010-04-21 Medimmune Llc Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica.
CN108314663B (zh) 2007-05-10 2022-05-13 多格伍德药品公司 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
MX2009014199A (es) 2007-06-18 2010-05-24 Organon Nv Anticuerpos para el receptor 1 de muerte programada pd-1 de humano.
WO2009014708A2 (fr) 2007-07-23 2009-01-29 Cell Genesys, Inc. Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
RU2491095C2 (ru) 2007-11-09 2013-08-27 Новартис Аг Применения анти-cd40-антител
US20110085970A1 (en) 2007-11-30 2011-04-14 Terrett Jonathan A Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
EP4321177A3 (fr) 2007-12-04 2024-05-08 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
EP2245065A1 (fr) 2008-01-23 2010-11-03 Xencor, Inc. Anticorps dirigés contre cd40 optimisés et leurs procédés d'utilisation
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
EP2279003A4 (fr) 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
KR20110039220A (ko) 2008-06-30 2011-04-15 교와 핫꼬 기린 가부시키가이샤 항ｃｄ27 항체
NZ590628A (en) 2008-07-16 2012-03-30 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef to dendritic cells
AU2010222928B2 (en) 2008-07-16 2012-11-29 Baylor Research Institute Antigen presenting cell targeted vaccines
US8168759B2 (en) 2008-07-18 2012-05-01 Bristol-Myers Squibb Company Compositions monovalent for CD28 binding and methods of use
WO2010007376A2 (fr) 2008-07-18 2010-01-21 Domantis Limited Compositions monovalentes pour la liaison à cd28 et procédés d’utilisation
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
EP2342229A1 (fr) 2008-09-12 2011-07-13 ISIS Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
KR101782570B1 (ko) 2008-12-09 2017-09-27 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
WO2010082912A1 (fr) 2009-01-15 2010-07-22 Avalon Pharmaceuticals Dérivés de composés aromatiques à noyaux multiples et utilisations comme agents anti-tumoraux
CA2751477C (fr) 2009-02-17 2019-08-27 Ucb Pharma S.A. Molecules d'anticorps ayant une specificite pour ox40 humain
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
WO2010104761A2 (fr) 2009-03-10 2010-09-16 Baylor Research Institute Anticorps anti-cd40 et utilisations de ceux-ci
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
EP2423228B1 (fr) 2009-04-20 2015-12-16 Kyowa Hakko Kirin Co., Ltd. Anticorps contenant igg2 ayant une mutation d'acide aminé introduite dans celui-ci
US20120076722A1 (en) 2009-05-14 2012-03-29 University Of Maryland, Baltimore Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
MX2012001417A (es) 2009-07-31 2012-07-03 Organon Nv Anticuerpos completamente humanos para atenuante de linfocitos b y t (btla).
RU2646139C1 (ru) 2009-09-03 2018-03-01 Мерк Шарп И Доум Корп. Анти-gitr-антитела
WO2011031063A2 (fr) 2009-09-09 2011-03-17 울산대학교 산학협력단 Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
EP3279215B1 (fr) 2009-11-24 2020-02-12 MedImmune Limited Agents de liaison ciblés contre b7-h1
MX346912B (es) 2009-12-07 2017-04-05 Univ Leland Stanford Junior Metodos para mejorar terapia con anticuerpos antitumor.
RU2012132442A (ru) 2009-12-29 2014-02-10 Киова Хакко Кирин Ко., Лтд. Антитело к cd27
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
KR20110085038A (ko) 2010-01-19 2011-07-27 울산대학교 산학협력단 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
JP5992340B2 (ja) 2010-02-18 2016-09-14 エフィミュヌＥｆｆｉｍｕｎｅ 抗ｃｄ２８ヒト化抗体
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
HUE045487T2 (hu) 2010-03-04 2019-12-30 Macrogenics Inc B7-H3-ra reaktív antitestek, immunológiailag aktív fragmenseik és alkalmazásaik
US8591900B2 (en) 2010-03-31 2013-11-26 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies
CA2795279C (fr) 2010-04-08 2020-05-05 Jn Biosciences Llc Anticorps anti-cd122
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
EP3363499A1 (fr) 2010-06-11 2018-08-22 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-tim-3
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
WO2013028231A1 (fr) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
ES2649155T3 (es) 2010-08-23 2018-01-10 Board Of Regents, The University Of Texas System Anticuerpos anti-OX40 y procedimientos de uso de los mismos
PE20131465A1 (es) 2010-09-09 2014-01-04 Pfizer Moleculas de union a 4-1 bb
CA2812046A1 (fr) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Agents a base d'arni modifies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EA035033B1 (ru) 2010-11-22 2020-04-20 Иннейт Фарма Са Способ лечения гематологического предракового или гематологического ракового заболеваний
WO2012075111A1 (fr) 2010-11-30 2012-06-07 Novartis Ag Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
CA2824278C (fr) 2010-12-20 2022-09-20 The Rockefeller University Modulation d'anticorps agonistes anti-tnfr
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
ES2734076T3 (es) 2011-02-17 2019-12-04 Kyowa Hakko Kirin Co Ltd Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
HUE044591T2 (hu) 2011-03-11 2019-11-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásuk
JP6220774B2 (ja) 2011-03-31 2017-10-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｉｃｏｓに対する抗体及びその使用
CA3019531A1 (fr) 2011-04-19 2012-10-26 Pfizer Inc. Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicite a mediation cellulaire dependante d'un anticorps (adcc) pour le traitement du cancer
AU2012245477C1 (en) 2011-04-20 2017-06-15 Medimmune, Llc Antibodies and other molecules that bind B7-H1 and PD-1
LT2699601T (lt) 2011-04-21 2018-03-26 Bristol-Myers Squibb Company Antikūnų polipeptidai, kurie antagonizuoja cd40
CN103687945B (zh) 2011-04-25 2016-10-12 第一三共株式会社 抗-b7-h3抗体
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
KR102046666B1 (ko) 2011-05-25 2019-11-19 이나뜨 파르마 염증성 장애의 치료를 위한 항-kir 항체
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
HUE037700T2 (hu) 2011-07-11 2018-09-28 Glenmark Pharmaceuticals Sa OX40-hez kötõdõ ellenanyagok és felhasználásuk
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
ES2861435T3 (es) 2011-11-03 2021-10-06 Univ Pennsylvania Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
KR102153374B1 (ko) 2012-03-15 2020-09-10 얀센 바이오테크 인코포레이티드 인간 항-cd27 항체, 방법 및 용도
WO2013152039A1 (fr) 2012-04-02 2013-10-10 The Trustees Of Columbia University In The City Of New York Composés, compositions, et procédés pour moduler la ferroptose et traiter des troubles excitotoxiques
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
KR101549637B1 (ko) 2012-06-08 2015-09-03 국립암센터 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
US9695133B2 (en) 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
US9268936B2 (en) 2012-07-27 2016-02-23 Mandiant, Llc Physical memory forensics system and method
CN104936982B (zh) 2012-08-03 2020-04-24 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
EP2890720B1 (fr) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions et méthodes de traitement du cancer
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
EP3263601B1 (fr) 2012-10-02 2021-11-24 Bristol-Myers Squibb Company Combinaison d'anticorps anti-kir et anti-pd-1 pour traiter le cancer
NZ705394A (en) 2012-10-11 2018-10-26 Daiichi Sankyo Co Ltd Antibody-drug conjugate
JP6272230B2 (ja) 2012-10-19 2018-01-31 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート
WO2014066532A1 (fr) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
JP2016011258A (ja) 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
WO2014065402A1 (fr) 2012-10-26 2014-05-01 株式会社ペルセウスプロテオミクス Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante
JP6693745B2 (ja) 2012-10-30 2020-05-13 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
SG11201504764SA (en) 2012-12-19 2015-07-30 Amplimmune Inc Anti-human b7-h4 antibodies and their uses
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
WO2014159835A1 (fr) 2013-03-14 2014-10-02 Genentech, Inc. Anticorps et immunoconjugués anti-b7-h4
WO2014140374A2 (fr) 2013-03-15 2014-09-18 Novo Nordisk A/S Anticorps monovalents anti-cd27
US20140322236A1 (en) 2013-03-15 2014-10-30 Sdix, Llc Anti-human adora2a antibodies
KR20160006168A (ko) 2013-03-18 2016-01-18 바이오서오엑스 프로덕스 비.브이. 인간화 항-cd134(ox40) 항체 및 이의 용도
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
MX2015016111A (es) 2013-05-24 2016-10-26 Medimmune Llc Anticuerpos anti-b7-h5 y sus usos.
EP3004169B1 (fr) 2013-05-31 2023-03-22 Sorrento Therapeutics, Inc. Protéines de liaison à l'antigène qui se lient à pd-1
WO2014197849A2 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anticorps anti-c10orf54 et leurs utilisations
WO2014209168A1 (fr) 2013-06-24 2014-12-31 Kim Ruslan Zynsonovich Communicateur automobile
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
RU2016107426A (ru) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
WO2015051149A1 (fr) 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Analogues de sorafenib et leurs utilisations
ES2707057T3 (es) 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
EP3076962A4 (fr) 2013-12-02 2017-10-18 The Trustees of Columbia University in the City of New York Modulation de la ferroptose et traitement des troubles excitotoxiques
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
JP6345787B2 (ja) 2013-12-20 2018-06-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗ａｎｇ２抗体とｃｄ４０アゴニストとの併用療法
WO2015109009A1 (fr) 2014-01-15 2015-07-23 The Trustees Of Columbia University In The City Of New York Analogues carbonylés de l'érastine et leur utilisation
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EP3113796A1 (fr) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
WO2015179236A1 (fr) 2014-05-21 2015-11-26 Pfizer Inc. Combinaison d'un anticorps anti-ccr4 et d'un agoniste a 4-1bb pour le traitement du cancer
JP6847666B2 (ja) 2014-05-28 2021-03-24 アジェナス インコーポレイテッド 抗ｇｉｔｒ抗体及びその使用法
AU2015265976B2 (en) 2014-05-29 2019-08-01 Ventana Medical Systems, Inc. Anti-B7-H3 antibodies and diagnostic uses thereof
CA2950581A1 (fr) 2014-05-30 2015-12-03 The Trustees Of Columbia University In The City Of New York Composes liant ras multivalents
WO2015188047A1 (fr) 2014-06-06 2015-12-10 University Of Maryland, Baltimore Anticorps monoclonaux anti-cd-137 présentant des capacités de liaison distinctes au fcγr pour le traitement d'un cancer ou d'une auto-immunité
EP3998079A1 (fr) 2014-06-06 2022-05-18 Bristol-Myers Squibb Company Anticorps dirigés contre le récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs procédés d'utilisation
EP3157563A1 (fr) 2014-06-23 2017-04-26 TheraMAB LLC Compositions et méthodes pour une immunothérapie efficace et sûre
WO2016005421A1 (fr) 2014-07-09 2016-01-14 Novo Nordisk A/S Dispositif d'administration de médicament motorisé
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN106573981A (zh) 2014-08-12 2017-04-19 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
RU2017108173A (ru) 2014-08-14 2018-09-17 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
CN106715469B (zh) 2014-08-27 2021-10-22 纪念斯隆-凯特琳癌症中心 抗体、组合物和用途
CA2951604A1 (fr) 2014-08-29 2016-03-03 Pablo Umana Therapie combinatoire d'immunocytokines a variant de l'il -2 ciblees therapie tumorale et d'anticorps anti-pd-l1 humaine
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
WO2016054638A1 (fr) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Anticorps dirigés contre le récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs procédés d'utilisation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US10259874B2 (en) 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
EP3212227B1 (fr) 2014-10-28 2020-01-15 Children's University Hospital Tübingen Traitement avec un anticorps anti-kir de patients pédiatriques atteints de leucémie lymphoblastique à précurseurs b (bcp-all)
HUE054075T2 (hu) 2014-10-29 2021-08-30 Seagen Inc CD40 elleni nem fukozilált antitestek adagolása és bevitele
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
PL3215532T3 (pl) 2014-11-06 2020-03-31 F. Hoffmann-La Roche Ag Przeciwciała anty-TIM3 i sposoby ich zastosowania
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
US9963509B2 (en) 2014-12-23 2018-05-08 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2017058716A1 (fr) 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Composés tricycliques
US20190008961A1 (en) * 2016-01-07 2019-01-10 The Broad Institute, Inc. Compounds and methods for increasing tumor infiltration by immune cells
WO2018118711A1 (fr) * 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Inducteurs de ferroptose à petites molécules
CN108409737B (zh) * 2017-02-10 2020-07-03 华东理工大学 4-甲氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其应用
US20200138829A1 (en) * 2017-05-24 2020-05-07 Ferro Therapeutics, Inc. Methods of cancer treatment
EP3645739A4 (fr) * 2017-06-28 2021-07-14 The Regents of the University of California Procédés et compositions pour le traitement du mélanome

Also Published As

Publication number Publication date
US20210251994A1 (en) 2021-08-19
CA3103629A1 (fr) 2019-12-19
WO2019241730A3 (fr) 2020-03-12
KR20210035805A (ko) 2021-04-01
JP2021528393A (ja) 2021-10-21
CN112638375A (zh) 2021-04-09
AU2019287765A1 (en) 2021-01-07
EP3806848A2 (fr) 2021-04-21
WO2019241730A8 (fr) 2020-02-06
WO2019241730A2 (fr) 2019-12-19

Similar Documents

Publication Publication Date Title
MA52889A (fr) Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
MA52897A (fr) Diminution de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaire
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
MA55805A (fr) Métodes de modulation de l'activité immunitaire
MA50122A (fr) Conversion de contexte de session
MX2020004519A (es) Moduladores de la vía de estrés integrada.
EA201991598A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
PE20201419A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
EA201892008A1 (ru) Соединения и способы лечения неврологических и сердечно-сосудистых состояний
WO2015120138A3 (fr) Agents modulant la signalisation rgmb-neogénine-bmp et leurs procédés d'utilisation
MY192425A (en) Polymorphs
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
DK3749669T3 (da) Ahr-modulatorer
MA53021A (fr) Composition de diacide oligosaccharidique d'alginate
EA202190974A1 (ru) Противовирусные пролекарства и их наносоставы
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
MA53664A (fr) Composés destinés au traitement de certaines leucémies
CL2018002074A1 (es) Composiciones y métodos para tratar infecciones.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
MA51795A (fr) Oligonucléotides pour moduler l'expression de tmem106b
EA202091471A1 (ru) Полиморфы
EA201992883A1 (ru) АНТИТЕЛА К TrkB
MA49827A (fr) Méthodes et compositions pour améliorer la santé de plantes et/ou le rendement de plantes
DK3801656T3 (da) Hudkompatibel silikonesammensætning
CL2019001469S1 (es) Cepillo de dientes.